Notably, their selection included patients from families affected by breast and ovarian cancer without a germline BRCA1 or BRCA2 mutation, while our selection was focused on the presence of tumor BRCA1 promoter hypermethylation. The gene discussed is BRCA2; the disease is neoplasm.